Revance Therapeutics (STU:RTI) EBITDA Margin % : -47.82% (As of Sep. 2024)

Revance Therapeutics EBITDA Margin % Chart

Revance Therapeutics Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
EBITDA Margin %		Get a 7-Day Free Trial					-37,867.74	-1,692.10	-328.01	-226.38	-124.18

Revance Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBITDA Margin %	Get a 7-Day Free Trial															-59.00	-210.17	-81.42	-46.43	-47.82

Competitive Comparison of Revance Therapeutics's EBITDA Margin %

For the Biotechnology subindustry, Revance Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Revance Therapeutics's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revance Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Revance Therapeutics's EBITDA Margin % falls into.

Revance Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Revance Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Revance Therapeutics's EBITDA Margin % for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Revance Therapeutics  (STU:RTI) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Revance Therapeutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Revance Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Revance Therapeutics Business Description